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Summary
Objective: Previous experiments have shown that addition of fragmented fibronectin can induce cartilage chondrolysis. In this study we
investigated the fate of the collagen- and cell-binding molecules Cartilage oligomeric matrix protein (COMP) and chondroadherin.
Design: Equine articular cartilage explants were stimulated with the C-terminal and the N-terminal heparin-binding fragments of fibronectin
respectively, and the conditioned media were analysed by both quantitative (ELISA) and qualitative (mass spectrometry, Western blots)
methods.
Results: Both COMP and chondroadherin were released in a dose-dependent manner upon stimulation with the Hep II (C-terminal
heparin-binding) fragment of fibronectin. The kinetics of release for the two components differed. Moreover, COMP was degraded while no
fragments of chondroadherin could be detected. Stimulation with Hep II also induced production of nitric oxide in a dose-dependent manner.
We compared effects of the Hep II fragment with that of Hep I (the N-terminal heparin-binding fragment of fibronectin) and found that while
Hep I did indeed elicit release of COMP and chondroadherin, the response was less potent, and production of nitric oxide was negligible. The
responses to both fragments were elicited within 24 h.
Conclusions: We suggest that the events described here may be early, critical stages in cartilage destruction preceding collagen destruction.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Joint diseases such as osteoarthritis (OA) and rheumatoid
arthritis (RA) affect a large proportion of the population.
Despite extensive research regarding the cause and
mechanisms of tissue involvement in these diseases, key
elements remain largely unknown. Consequently diag-
nostic tools routinely used today are insensitive to the early
events in tissue damage, processes which could predict
and may determine the course of disease.
Studies on RA suggest a dichotomous nature of
the disease. On one hand there is the inflammatory
component, often with extra-articular symptoms, and on the
other hand the progressive destruction of joint tissues1.
Recent therapy for RA has focused upon the blocking of
cytokine pathways, particularly of tumour necrosis factor 
(TNF-) (for review see2,3). The anti-TNF treatment in RA
relieves symptoms in some two thirds of the patients by
inhibiting the inflammatory component. However, although
the destruction of cartilage appears inhibited, this occurs
only after a lag time4, indicating indirect effects. How these
two processes of inflammation and destruction interrelate
and possibly regulate each other is not clear.
One hypothesis is that proteolytic fragments formed in
the destruction process may promote further destruction of
the cartilage. Analyses of joint fluid from RA patients have
revealed elevated levels of inflammatory cytokines5–7,
immunoglobulins8,9 and understandably, elevated levels of
degraded extracellular matrix components originating
from cartilage and bone. One such extracellular matrix
component is fibronectin10.
Fibronectin is found throughout the body’s extracellular
matrices and is particularly prominent in blood. It is a
classical example of a protein with a modular structure,
containing several functional domains. These can readily
be separated from each other by proteolysis. The domains
thus separated will retain their functionality in isolation
(see11 and references therein). In addition, these isolated
domains have been shown to modulate the ability of other
domains to influence cell activities12.
Synthesis of fibronectin is up-regulated in cartilage in OA
and RA, and proteolytic fragments have been identified in
patients (for review see13). Pivotal experiments on func-
tional characteristics of fragments of fibronectin generated
by in vitro proteolysis were performed by Homandberg
et al14. Proteolytic fragments of Fn were added to
bovine explant cartilage cultures and shown to induce the
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degradation of cartilage, as monitored by the release of
matrix metalloproteinases (MMPs) and proteoglycans to
the medium. The intact protein did not induce these effects.
The study demonstrated that proteolytic processing of
extracellular matrix components may produce fragments
with properties very different from the parent molecule and
that these most likely contribute to the ongoing process of
destruction, supporting the hypothesis outlined above.
Cartilage as a tissue is characterized by an extensive
extracellular matrix. This matrix is synthesised and main-
tained by a single cell type, the chondrocyte, which
sparsely populates it. The matrix is a fibrous collagen
network that enmeshes the large aggregating proteo-
glycan, aggrecan. The extreme fixed negative charge
conferred upon the tissue by aggrecan via its gly-
cosaminoglycan side chains acts to retain and imbibe
water, while the collagen fibre network resists any swelling
of the tissue. The result is a structure capable of efficiently
withstanding and distributing load. The integrity of
both these structures is necessary for adequate tissue
function.
Disease that progressively affects the cartilage of a joint
will lead to the degradation of the major proteoglycan,
aggrecan15 at an early stage. Conversely, loss of the
integrity of the collagen network appears to be a later, and
perhaps more critical event16. Studies suggest that up to a
point, aggrecan lost can be replaced. Indeed, in reactive
arthritis, an acute, resolvable joint disease, levels of proteo-
glycans released from the articular cartilage into the syno-
vial fluid increase to high levels and then decrease upon
healing17.
The organization of the collagen network is modulated
and maintained by the many accessory molecules binding
to collagen (for references see18). These proteins may bind
the collagen fibre, and may facilitate or prevent interactions
with other collagen fibres in the network (e.g. decorin19,
biglycan20, fibromodulin21 and collagen IX22). These
accessory molecules also interact with a range of other
extracellular matrix components, as well as cell surface
receptors e.g. integrins (e.g. chondroadherin23) and
heparan sulphate proteoglycans (e.g. PRELP24). In this
manner these accessory molecules may serve to link the
collagen network to the chondrocyte.
In this study, we present data that expands the concept
of chondrolysis induced by extracellular matrix fragments,
to include information on the fate of molecules contributing
to the collagen network integrity. We show that Fn-f causes
not only loss of proteoglycan, but also induces the degra-
dation and/or release of at least two molecules primarily
present in two different compartments, COMP and chon-
droadherin. This information supports the hypothesis that
proteolytic fragments of matrix constituents can augment
the destruction of cartilage, and furthers our knowledge on
potential mechanisms underlying that destruction.
Materials and methods
Both Fn-f Hep I and Fn-f Hep II are purified proteolytic
fragments derived from human plasma fibronectin. The Fn-f
Hep II may vary at its C-terminal end, probably due to
manufacturing procedures. We have found that some
preparations contain the adjoining IIICS segment while
others do not. This segment contains the cell-binding
sequences LDV25 and REDV26. By mass spectrometry
we did not detect peptides from the CSIII region in the
preparations that were used in the experiments.
The fragments we have used are as follows:
– the 40 kDa fragment from the C-terminal part of
fibronectin containing the heparin-binding domain II.
This will be referred to as Fn-f Hep II (GIBCO Life tech.
Cat no 12158-010, lot no.1030070).
– the 30 kDa fragment from the most N-terminal portion
of fibronectin, containing the heparin-binding domain I.
This will be referred to as Fn-f Hep I (Sigma Cat no.
F-9911, lot no. 119M4070). The domains are indicated
in the schematic drawing of fibronectin in Fig. 1.
To verify identity and determine purity, aliquots of
Fn-f Hep II and Hep I were digested with trypsin and
the resulting peptides analysed by MALDI-TOF mass
spectrometry using standard protocols.
The porcine mucosal heparin, culture tested, was
from Sigma. N-iminoethyl – lornithine (L-NIO) was from
Calbiochem (U.S.A.). Dulbecco’s minimal Essential
medium, 100× Minimum essential amino acids, Penicillin/
Streptomycin and L-Glutamine were purchased from
GIBCO Life. Polymixin B sulphate was from Sigma.
Calphostin C, Herbimycin A and LNIO were from
Calbiochem.
Western blots were performed using the Bio-Rad system.
Membranes used were Hybond C from Amersham Life
Sciences.
EXPLANT CULTURES
Cartilage was dissected from the metacarpophalangeal
joint of horses aged 4–5 years. Full depth slices of cartilage
were diced and mixed to randomise. Cartilage was cultured
at 37oC under an atmosphere of 5% CO2 in serum-
free DMEM supplemented with 100 Units/ml Penicillin/
Streptomycin, 1× essential amino acids and 2 mM
L-Glutamine. Polymyxin B was included in medium at a
concentration of 5 µg/ml.
The explant cultures were pre-incubated for 48 or 72 h to
allow adaptation to culture conditions, with medium
changed every 24 h. Cultures were then stimulated by the
addition of Fn-f to the culture media, at a final concentration
of 0.1 −1.0 µM for 48 or 72 h. In all cases the medium was
changed and the stimulus renewed at 24 h intervals. In
experiments with Fn-f in the presence and absence of
heparin, tissue explants were treated for 72 h after pre-
incubation. In these experiments the explants were incu-
bated in fresh media containing 100 µg/ml heparin for 1.5 h
prior to the addition of the Fn-f. This procedure was
repeated with each medium change.
In experiments using inhibitors, the tissue explants were
treated for 48 h after pre-incubation. The protein kinase C
inhibitor Calphostin C was used at 1 µM and the Src
inhibitor Herbimycin A was used at 5 µM. The iNOS inhibitor
L-NIO was used at concentration of 1 mM. The inhibitors
were added concomitantly with the Fn-f to see effect, or on
their own to parallel cultures as controls. Fn-f was used at
200 nM in Calphostin C and Herbimycin A experiments,
and at 1.0 µM concentration in L-NIO experiments.
The media were recovered and stored at −20oC until
further analysis with no further treatment. After each exper-
iment the wet weight of the cartilage was determined before
storage at −20oC.
SDS-PAGE AND WESTERN BLOTS
Media from triplicate samples were pooled and volumes
were adjusted to represent equal weights of cartilage. The
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samples were electrophoresed under reducing as well as
non-reducing conditions on 4–16% gradient SDS-
Polyacrylamide mini-gels27. Western blotting28 was per-
formed using the Bio-Rad system. Gels were blotted for
90 mins at 100 V. Membranes were probed with primary
antibody raised in rabbit (see below), followed by a swine-
anti-rabbit secondary antibody conjugated to horse-
radish peroxidase (DAKO). Bands were visualised using
enhanced chemiluminescence substrate by a method
modified from that of Thorpe et al 29. In some experiments
Western blots were probed with a polyclonal antibody
against COMP followed by a polyclonal antibody against
chondroadherin (see Fig. 2D). These two antibodies do not
react with the same antigens as shown by blots of articular
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Fig. 1. Domains of fibronectin. A schematic drawing of a fibronectin monomer is depicted in A. The fragments used in these experiments
correspond to Hep I and Hep II respectively. Figures B and C show peptide coverage for the commercially obtained Hep I and Hep II
fragments respectively. The domain is boxed in, and peptides detected are shadowed grey. In B, peptides that were also found in the Hep
II preparation are underlined.
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cartilage extracts (Fig. 2D). Sequential blotting circum-
vented the stripping of membranes, a procedure where
protein may be lost from the membrane.
ANTIBODIES
Chondroadherin was detected with a polyclonal antibody
against the bovine protein30. A polyclonal antibody against
bovine COMP31 was used. Both were shown to detect
the corresponding equine proteins (data not shown). The
anti C-terminal COMP antibody was raised against a pep-
tide of the ten most C-terminal amino acid residues of
equine COMP, which was coupled to keyhole limpet hemo-
cyanin using standard protocols. This antibody was shown
to react with equine COMP in Western blots (data not
shown).
In Western blots, the two polyclonal antibodies were
used at a dilution of 1:1000 in block buffer (Tris-buffered
Fig. 2. The Fn-f Hep II induces release and degradation of COMP and release of chondroadherin. Cartilage explant cultures were stimulated
with increasing concentrations of Fn-f Hep II (µM) and the media assayed for the release of extracellular matrix components and NO. (A) The
COMP content in medium was measured by ELISA and correlated to wet weight of cartilage. The release of COMP is dose-dependent. (B)
The release of glycosaminoglycan to the medium was assayed by DMB assay and found to be dose-dependent. (C) Western blots were
probed with an anti-chondroadherin antibody, band density measured and plotted and show that chondroadherin is also released in a
dose-dependent manner. (D) Western blot of medium samples showing the degradation and release of COMP over the course of one
experiment. Media from triplicate samples were pooled, corrected for the wet weight of cartilage and electrophoresed under non-reducing
(D–F) and reducing (G) conditions. Membranes were probed for COMP using a polyclonal anti- COMP antiserum (D, F and G), a polyclonal
antiserum against chondroadherin (D), and a polyclonal against C-terminal COMP (E). Intact pentameric COMP is released initially (C,
position indicated by white arrowhead). Increased release and degradation of COMP is induced upon stimulation with Fn-f Hep II (Days 4–6,
Stimulation). The position of intact COMP monomer is indicated by a bold arrow, whilst position of degraded COMP monomer is indicated
in C, E and F by a light arrow. Monomer COMP runs at higher apparent molecular weight when reduced. Release of chondroadherin is also
induced, though it does not appear to be degraded (indicated in D by Anti-CHAD). Results are from one typical experiment out of several.
Data points are from samples analysed in triplicate. Error bars indicate standard deviation of the mean.
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saline pH 7.4, 0.2% Tween-20, 5% milk). The anti-C-
terminal COMP antibody was diluted at 1:250 in block
buffer.
COMP ELISA
The COMP content of conditioned media was deter-
mined using an inhibition ELISA32,33 employing equine
tendon COMP as standard and a polyclonal anti-equine
COMP antibody for detection. The concentration of COMP
was calculated from the standard curve, and normalized to
the wet weight of the cultured cartilage.
GLYCOSAMINOGLYCAN ASSAY
The release of glycosaminoglycans was analysed using
the dimethylene blue assay34.
MASS SPECTROMETRY OF PROTEINS RELEASED INTO THE MEDIA
Aliquots of medium equalized on the basis of wet weight
of the cultured cartilage were separated by SDS-PAGE and
stained by Coomassie Blue. Protein bands that increased
after addition of Fn-f Hep II were cut out and identified
by MALDI-TOF mass spectrometry after trypsin digestion
using standard protocols.
GRIESS ASSAY
The nitric oxide content of conditioned media was
determined by the Griess reagent assay35.
DATA ANALYSIS
Experiments were performed with triplicate wells, and
data analysis of each well was performed in triplicate.
Experiments have been repeated several (2–10) times. All
experiments included positive (treatment with Fn-f Hep I)
and negative (no additions) controls. Results relative to
these controls were consistent and reproducible. Graphs
are based on one representative experiment, and error
bars indicate standard deviation of the mean.
Results
MALDI-TOF mass spectrometry identified the fibronectin
fragments and matched the sequence for respective
domains (coverage indicated in Fig. 1B and C). No con-
taminants were detected. Interestingly, despite published
data to the contrary36, peptides from the adjoining CSIII
domain could not be detected. A preparation from a differ-
ent supplier did contain such peptides (data not shown).
This preparation was not used. While the preparation of
Fn-f Hep II appeared to contain contaminants from the Hep
I domain (underlined in Fig. 1B), the Fn-f Hep I preparation
did not contain any peptides from Hep II.
Cartilage explants prepared as described and subjected
to freeze–thaw cycles before being placed in culture,
did not release the components upon stimulation, as
determined per Western blot (data not shown).
SDS-PAGE and mass spectrometry were used to identify
components released to the medium upon stimulation with
Fn-f Hep II. Matrix metalloproteases MMP-1 and MMP-3
were identified as two such components (data not shown).
The most prominent band on Coomassie-stained gels
was identified as COMP by trypsin digestion and mass
spectrometry (data not shown). Results in Fig. 2A and B are
from experiments where cultures were treated for 48 h with
the Fn-f, and the data from the last 24 h of treatment.
Release of COMP quantified by ELISA (Fig. 2A) was shown
to be dose-dependent. The release of glycosaminoglycans
was dose-dependent (Fig. 2B), while rates of proteoglycan
synthesis remained constant in non-stimulated culture
as determined in initial experiments by [35S]-sulphate
incorporation (data not shown).
Fig. 2D illustrates the release/degradation process over
time at the dose of 250 nM. Cultures were stimulated for
three days with Fn-f (days 4, 5 and 6) and medium
corresponding to release from 16.5 mg explant was separ-
ated on 4–15% SDS-polyacrylamide gels. Western blots
revealed that a large proportion of the COMP released was
degraded (see Fig. 2D). This degradation was dose-
dependent and increasing concentrations of Fn-f lead to
the appearance of additional yet smaller bands (data not
shown) presumably resulting from the further degradation
of the larger fragments.
At initiation of culture (Days 1 to 3 of pre-culture, Fig. 2D)
we noted the release of some intact COMP (Fig. 2D, white
arrow), as well as some fragmented and monomeric COMP
(indicated by a light arrowhead and a bold arrowhead
respectively, in Fig. 2D). After several days in culture, these
bands are no longer detectable (Day 5 and 6 Controls).
Only smaller amounts of pentameric COMP retained as a
complex at the top of the gel may be detected at these later
time points. Addition of the Fn-f Hep II resulted in an
immediate (within 24 h) and progressive release of
degraded COMP as seen on Days 4, 5 and 6 of stimulation.
Western blots of both non-reduced (NR) and reduced
(Red) gels consistently showed a band never seen in
controls, and always seen in Fn-f Hep II treated samples.
This band appears slightly smaller in size than monomer in
both NR and Red gels (indicated in Fig. 2F and G by
arrowhead). Though non-reduced gels were found to be
particularly useful for gaining an overall picture of the total
fragmentation of COMP, the appearance of the distinctive
band just below the position of the monomer was often
more clearly demonstrated using reduced gels. Reduced
gels also provided a better estimation of the relative pro-
portion of degraded COMP. Fig. 2F and G show the same
samples (from day 6) run on NR and Red gels respectively
probed with the same antibody.
In order to determine if the degradation of COMP was at
one end, duplicate Western blots were probed with anti-
bodies raised against the C-terminal and the whole protein
respectively (Fig. 2E and F). The C-terminal antibody
recognized the same bands as the polyclonal antibody, with
the exception of the fastest migrating bands in Fn-f treated
sample, which was not detected. These bands thus lack
the C-terminal part, while the other bands represent
components cleaved only at the N-terminus.
OTHER MATRIX MOLECULES ARE ALSO RELEASED
Analysis using SDS-PAGE in combination with mass
spectrometry identified a second collagen binding extra-
cellular matrix molecule, chondroadherin, that was
released at increased levels after stimulation with the Fn-f
Hep II (Fig. 2C, incubation three days with Fn-f, sample
corresponding to the last day of incubation).
While it is clear that chondroadherin was released in a
dose-dependent manner (Fig. 2C), the release over time
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differed from that of COMP. In contrast to COMP, chondro-
adherin was released in intact form, as demonstrated by
SDS-PAGE and Western blots (Fig. 2D).
FN-F HEP II INDUCES PRODUCTION OF NO
In our experiments, stimulation with Fn-f Hep II also
produced NO in a dose-dependent manner (Fig. 3A).
Cultures were stimulated for two days with Fn-f, data is
from last day of incubation. Use of L-NIO, an inhibitor of
inducible nitric oxide synthase (iNOS) at 1 mM blocks NO
production efficiently (Fig. 3B) but has no effect on the
release (Fig. 3B) and degradation (not shown) of COMP.
This suggests that COMP fragmentation is parallel to, but
not dependent on the production of NO.
STIMULATION WITH OTHER EXTRACELLULAR MATRIX
COMPONENTS DOES NOT MIMIC FN-F
In order to determine whether the response elicited by
the Fn-f Hep II was specific or merely a general distress
response, explant cultures were incubated with other iso-
lated structures relevant to the extracellular matrix of carti-
lage. These structures were chosen to contain domains
with activities analogous to those of domains found in
fibronectin. Explant cultures were incubated for 48 h
with these structures, and the medium was changed and
stimulus renewed after 24 h.
Thus, 1 mM concentrations of a peptide (GRGDSP)
which represents the binding site of fibronectin to the
5 1 integrin did not stimulate release or degradation of
COMP; neither did it stimulate NO production. Heparin-
binding PRELP37 at 1 µM (30 µg/ml), or v3-binding
Osteopontin38 at 12 nM (400 ng/ml) showed no effect (data
not shown).
Attempts were made to inhibit the effects of added
fragment by pre-incubation with heparin (Fig. 4). In exper-
iments where cartilage explants were pre-incubated with
100 µg/ml heparin for 1.5 h prior to the addition of the Fn-f
Hep II, COMP release measured by ELISA was reduced to
intermediate levels as compared to Fn-f Hep II alone at the
same time point (Fig. 4C). For example, on day 5 levels of
COMP released were reduced from 1145 µg/ml/g wet
weight in Fn-f Hep II treated to 790 µg/ml/g wet weight in
cultures treated with both Fn-f Hep II and heparin (Fig. 4C).
The decrease of fragmentation is most clearly seen on
Western blots of samples of reduced samples (Fig. 4A and
B). At the same time, production of NO is also decreased
(Fig. 4D).
THE N-TERMINAL FN-F HEP I SHOW ONLY PARTIAL EFFECTS
We repeated the experiments performed with Fn-f Hep II
using the N-terminal fragment of fibronectin containing the
Hep I domain (Fn-f Hep I) (Fig. 5). Western blots of the
conditioned media show that this fragment also induced
the release and degradation of COMP (Fig. 5D), but in
these experiments this fragment was less potent than the
Fn-f Hep II fragment on a molar basis (Fig. 5A). The release
of COMP was dose-dependent as shown by Western blots.
The fragmentation of COMP resulted in the appearance of
the signature fragment just below the monomer (Fig. 5D)
also observed in experiments with Fn-f Hep II. Hep I also
induced the release of chondroadherin, but did not seem to
be dose-dependent at these concentrations (Fig. 5B). In
striking contrast to results with Fn-f Hep II, the Fn-f Hep I
failed to induce NO production (Fig. 5C).
HERBIMYCIN A INHIBITS DEGRADATION OF COMP
In order to investigate which signaling pathways might be
involved in transducing the effect of the Fn-f Hep II,
experiments were performed where explant cultures were
co-stimulated with Fn-f Hep II and a known kinase inhibitor.
Media corresponding to release from 10.4 mg cartilage
explant tissue was separated on 4–16% mini-gels under
non-reducing conditions.
The inhibitor Calphostin C (1 µM) is an inhibitor of PKC
kinases. Co-incubation of this compound with Fn-f Hep II
stimulated cultures did not inhibit the release and fragmen-
tation of COMP. Co-incubation with 5 µM Herbimycin A,
an irreversible inhibitor of Src-kinases diminished the
degradation of COMP (Fig. 6). However, the release of
chondroadherin did not appear to be affected in either
case.
Control experiments, where Fn-f was added with DMSO
(the solvent in which the inhibitors were dissolved) did not
show inhibition of the Fn-f effect. Experiments where the
inhibitor was added alone did not appear different from
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untreated controls, indicating that the inhibitory effect
achieved in co-incubation with Herbimycin A was indeed
due to the effect of the inhibitor itself.
Discussion
Our experiments demonstrated the chondrolytic effect of
two fibronectin fragments in an equine cartilage explant
system. We have focused on the fate of two molecules not
previously studied, namely COMP and chondroadherin.
These molecules are particularly relevant since they are
involved in maintaining the integrity of the collagen network
in cartilage. In cartilage destruction, it is conceivable that
the ultimate degradation of the collagen network would
involve an early degradation and/or release of such
components.
THE RELEASE OF PROTEOGLYCAN
The release of proteoglycan in our system is in keeping
with the results found for other fibronectin fragments in a
bovine system. The release of proteoglycans from bovine
explant articular cartilage cultures has been previously
shown to be a process requiring cell activity, since freeze-
thaw treatment precluded the process14. This is also the
case for the extracellular matrix constituents in the current
experimental set-up with Hep II stimulation (data not
shown).
THE RELEASE OF COMP
A major component released into the medium from
the cartilage stimulated with the Fn-f Hep II fragment
was COMP as shown by SDS-PAGE/mass spectrometry.
Interestingly, COMP is released from affected cartilage in
joint disease in RA as well as OA. Both synovial fluid and
serum levels of COMP are elevated in these diseases39–41.
COMP is present in certain tissues e.g. blood vessels42
and tendon43, but is particularly abundant in cartilage
extracellular matrix31. It is a large (5×87 kDa) homo-
pentameric protein, where the 5 monomers are joined
at their N-termini, leaving the C-terminal globular domains
free to associate with other extracellular matrix
components44. This structure is highly suggestive of a
function in linking other structures via interactions with the
five identical C-terminal globular domains. It has been
shown that COMP binds collagen with its C-terminal globu-
lar domains45. COMP appears to accelerate collagen
fibrillogenesis in vitro by binding several collagen mol-
ecules, thereby contributing to the assembly of the collagen
scaffolding of cartilage. (Rosenberg, Mo¨rgelin, Heinega˚rd,
unpublished).
The fragmented COMP that we demonstrated here in
Fn-f stimulated cultures are monomerical and therefore
lack this catalytical activity. In some cases these fragments
also lack the C-terminal collagen-binding domain. Thus,
they are unlikely to be able to contribute to the collagen
fiber network stability and may not be able to promote
and/or sustain attempts to repair it. This may be an early
step contributing to the disintegration of cartilage.
THE RELEASE OF CHONDROADHERIN
In the analysis of the conditioned media from exper-
iments by SDS- PAGE/proteolysis/mass spectrometry, we
discovered that a second collagen-binding ECM protein
was being released. This protein, chondroadherin, is a
small 38-kDa leucine rich repeat (LRR) protein and is
primarily found in cartilage, where it is concentrated peri-
cellularly and in the territorial matrix46. Chondroadherin
binds cells via their 21 integrins23 and also binds colla-
gen with high affinity47. With its multiple affinities includ-
ing its cell-binding activity, chondroadherin is uniquely
positioned to relay information from the surrounding matrix
to the cell.
Fig. 4. Effects of Fn-f Hep II can be partially inhibited by co-
incubation with heparin. Heparin (100 µg/ml) is added 1.5 h prior to
addition of Fn-f Hep II. Degradation of COMP (A, B) is shown by
Western blot of reduced gels probed for COMP. Release (C) of
COMP as well as levels of nitric oxide (D) produced are reduced to
intermediate levels, as shown by ELISA for COMP content and
Griess assay of conditioned media. Results are from one exper-
iment out of two with similar results. Data points are from samples
analysed in triplicate and error bars indicate standard deviation of
the mean.
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Chondroadherin has not yet been implicated in joint
disease, and neither intact nor fragmented chondroadherin
have been found in synovial samples of RA and/or OA
patients. Preliminary data indicate that already in early
stages of osteoarthritis, chondroadherin levels are
decreased in the articular cartilage (Ma˚nsson, Lorenzo and
Heinega˚rd unpublished). In IL-1-treated bovine explant
cultures chondroadherin stores are completely depleted
after 12 days of culture (Heathfield, Ma˚nsson and
Heinega˚rd, unpublished results). In further support for the
implication of chondroadherin in cartilage pathology, treat-
ing explant cultures with APMA to activate endogenous
pro-metalloproteases induced release of chondroadherin
molecules attached to collagen II to the medium, but only in
intact form47.
In our experiments, chondroadherin was released at
intermediate to high levels immediately when culture was
started, probably reflecting adaptation to culture conditions.
The initially high levels of chondroadherin released
decreased during pre-culture. Release was induced by the
treatment with Fn-f. However, levels peaked on day 1 or 2
of stimulation, and decreased again at different rates. This
pattern of release of chondroadherin would suggest a more
rapid course for loss of chondroadherin than for loss of
COMP. The absence of detectable chondroadherin levels in
synovial fluid of RA and OA patients may reflect that this
release is an event so early as to already have taken place
when medical care is sought for joint disease. Thus, an
intriguing question which remains to be further clarified
concerns the timing and relation between chondroadherin
release and that of COMP.
THE PRODUCTION OF NO
Stimulation of cartilage explant cultures with cytokine
Interleukin-1 (IL-1) leads to the release of proteoglycan and
production of nitric oxide (NO), a signalling molecule48. NO
has been implicated in RA (for review, see49).
In our experiments, treatment with Fn-f Hep II has
consistently given a reproducible dose-response curve (a
total of 10 experiments), though the absolute values have
varied. This may be due to different batches of reagent, or
the stability of the Griess reagents. However, a positive
control was always included in all experiments comparing
NO production.
In our experiments, the Fn-f Hep II induced NO produc-
tion in a dose-dependent manner, whereas the Fn-f Hep I
did not. There are reports where Fn-f Hep I has been
reported to stimulate NO production in monolayer culture of
human primary chondrocytes50. However, the levels
Fig. 5. Effects of Fn-f Hep I. Cartilage was stimulated by addition of Fn-f Hep I using the same protocol as for Fn-f Hep II. The effects were
principally the same as Hep II, though the response was less pronounced. (A) Media from triplicate samples were pooled, corrected for the
wet weight of cartilage and electrophoresed under reducing conditions. Western blots were probed for COMP and the resulting bands
assayed by densitometer scanning and plotted in a graph. Open bars indicate intensity of bands in samples treated with molar concentrations
of Fn-f Hep I. Filled grey bars indicate intensity in band of sample treated with 0.25 µM Fn-f Hep II. Similarly, in (B) the release of
chondroadherin (CHAD) was assayed by densitomeric scanning of Western blot bands. Little or no nitric oxide production could be detected
(C) in Griess assay of conditioned media. (D) shows a Western blot of non-reduced samples probed for COMP, showing the increasing
fragmentation of COMP in increasing doses of Fn-f Hep I. The arrow indicates the fragmented monomer. Extract: extract of bovine articular
cartilage, Control: non-treated, 0. 01 0. 1 0. 25 and 1. 0 µM concentrations of Fn-f Hep I used to treat explants. Data is from one experiment
performed in triplicate.
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reported are low and lie below the level of detection of our
assay. It is clear that Fn-f Hep II is more efficient at inducing
NO response than Fn-f Hep I.
THE LIGAND FOR THE FN-F HEP II
Our results show that co-incubation of Fn-f Hep II with
heparin partially inhibits the response to the Fn-f Hep II
fragment. The lower levels of COMP released may reflect
either an inhibitory process where the effect of the Fn-f Hep
II is partially blocked or an altered kinetics of release where
release of COMP is slowed. This is in keeping with results
from Yasuda et al 51. In their experiments, incubation with
the heparin-binding peptide (WQPPRARI) blocks the
production of MMPs induced by the Fn-f Hep II.
Fibronectin fragments have been shown to bind to the 5
integrin subunit, indicating that some fragments may inter-
act with the 51 integrin to transduce their effects52,53.
However, our data suggest an additional receptor for other
fibronectin fragments.
Inhibition of COMP release and degradation was
achieved by co-incubation with a Src-kinase inhibitor, but
not with an inhibitor of PKC kinases. Intriguingly, the
release of chondroadherin is not affected by Src inhibition.
It is possible that release of COMP and chondroadherin are
the result of different signaling pathways.
THE FN-F HEP I
The Fn-f Hep I used here includes the 29-kDa fragment
reported to be the most potent fragment of those used to
stimulate bovine cartilage14. In our experiments however,
this is not the case. On the contrary, though the Fn-f Hep I
does seem to be able to elicit some degradation and
release of COMP, it is less potent than the Fn-f Hep II.
RELEASE OF CARTILAGE COMPONENTS MAY BE USEFUL AS
MARKERS FOR DISEASE
It is worth noting that there are interactions between the
three molecules in focus here. COMP is found primarily
pericellularly in adult cartilage, while in developing cartilage
it is also found interterritorially, further away from the
chondrocyte54. COMP can bind collagen44 and the
N-terminus of fibronectin55. Chondroadherin, a component
of the pericellular compartment, can both bind collagen47
and interact with the chondrocyte via the integrin 2123.
This integrin is also a receptor for collagen56,57. This
network of interactions is but one of several such networks
in existence in the matrix, where the components are linked
to each other and ultimately link back to the chondrocyte.
Even subtle disturbances of such a network in the matrix
may lead to changes in interactions with cell surface
receptors, and thereby effect a change in the signals to the
chondrocyte from its surrounding matrix. The results shown
may describe an example of early effects of disturbing such
a network of interactions.
The degradation or incapacitation of the accessory mol-
ecules contributing to the integrity of the collagen network
will likely precede an ultimate failure of the network. As the
different components are affected at different times, it
should be possible to monitor the progression of tissue
destruction and the involvement of different compartments
by demonstrating the degradation and release of extra
cellular matrix molecules characteristic for a given compart-
ment in the cartilage. Knowledge concerning the sequence
of events would potentially be of great use in patient
care for diagnosis, monitoring and estimation of prognosis.
Elucidation of the responses reported here, in particular the
timing and possibility of involvement of different signaling
pathways, would be a valuable step on the way to under-
standing more fully the process of cartilage destruction in
joint diseases.
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